www.squadscarf.com • Professional Insights • Expert Commentary • Resource Center
www.squadscarf.com

Budget Guide,use of dulaglutide could help improve glycemic control in youth

Dulaglutide Under 18: Understanding Its Use and Approval for Youth with Type 2 Diabetes 29 Jul 2019—The purpose of this study is to evaluate a new formulation ofdulaglutide(study drug) administeredunder18+ years old. Volunteers.

:is approved for use in adults but not yet for youths

A
Lillian Martin

researches '' content performance and visibility and provides detailed analysis across Facebook and Instagram

Published on

Executive Summary

use of dulaglutide could help improve glycemic control in youth 29 Jul 2019—The purpose of this study is to evaluate a new formulation ofdulaglutide(study drug) administeredunder18+ years old. Volunteers.

The question of dulaglutide under 18 is a crucial one for healthcare providers and families managing type 2 diabetes mellitus (T2DM) in younger individuals. While dulaglutide is a well-established treatment for adults, its application in pediatric populations has been a subject of ongoing research and evolving guidelines. This article delves into the current understanding of dulaglutide for individuals aged 10 to less than 18 years old, examining its efficacy, safety, and regulatory status, with a focus on providing verifiable information.

For years, the primary treatment for T2DM in adults has included medications like dulaglutide, a GLP-1 receptor agonist that works by reducing blood sugar and also aids in weight loss by reducing food cravings and increasing insulin production. However, the unique physiological considerations of children and adolescents meant that its use in this demographic required careful investigation.

FDA Approval and Clinical Trials for Youth

A significant development in the use of dulaglutide for younger populations is its FDA-approved status for patients aged 10 to less than 18 years old with type 2 diabetes. This approval stems from robust clinical trials, including the AWARD-PEDS trial, which specifically investigated the safety and efficacy of Trulicity (dulaglutide) in this age group. These studies have provided critical data on how dulaglutide impacts glycemic control in adolescents.

One such study, published in 2022, demonstrated that twenty-six weeks of weekly dulaglutide therapy lowers A1C by nearly a full percentage point among teens and pre-teens with T2DM. The research indicated that treatment with dulaglutide at a once-weekly dose of 0.75 mg or 1.5 mg was superior to placebo in improving glycemic control. Specifically, over a 26-week trial, 51% of youth (ages 10 to <18 years) treated with once-weekly dulaglutide achieved an HbA1c below 7% versus only 14% on placebo. This suggests that dulaglutide can be a valuable tool in achieving target glucose levels.

Further research, such as a study from 2023 on the effects of once-weekly dulaglutide in juvenile type 2 diabetes, has also highlighted its potential. While a case report in 2021 demonstrated the feasibility of using a non-approved long-acting GLP-1-RA (dulaglutide) in adolescents with T2D under special circumstances, the formal approval signifies a broader acceptance and availability of the medication for this age group.

It is important to note that while dulaglutide is approved for use in this age range, Trulicity should not be used in children under 10 years of age, as its safety and effectiveness in lowering blood sugar in this younger demographic have not been established.

Efficacy and Dosage for Pediatric Patients

The efficacy of dulaglutide in youth with T2DM is primarily measured by its ability to improve glycemic control, as indicated by reductions in HbA1c levels. Clinical trials have shown that dulaglutide effectively lowers A1C and contributes to achieving target glycemic control.

The recommended starting dose for dulaglutide injection in this age group is 0.75 mg SC once weekly. For additional glycemic control, this dose can be increased to 1.5 mg once weekly. This dosage regimen is consistent with the goal of optimizing blood sugar management while monitoring for any adverse effects.

Safety and Side Effects

As with any medication, understanding the safety profile and potential side effects of dulaglutide is paramount. While studies have shown dulaglutide to be effective and safe for improving glucose control in youth, it is essential to be aware of potential risks. The Mayo Clinic and MedlinePlus Drug Information provide comprehensive details on the known side effects. Common side effects can include nausea, vomiting, diarrhea, and abdominal pain.

More serious, though less common, side effects can occur. Dulaglutide causes thyroid C-cell tumors in rats, and it is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Therefore, it is not recommended for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Healthcare providers will carefully assess each patient's medical history and current health status to determine if dulaglutide is an appropriate treatment option. Ongoing monitoring is crucial to manage any emergent side effects.

Future Directions and Research

The approval of dulaglutide for use in individuals aged 10 to less than 18 years old represents a significant advancement in the treatment of type 2 diabetes in youth. However, research

Related Articles

Frequently Asked Questions

Here are the most common questions about .

Dulaglutide Improves HbA1c for Youth With Type 2 Diabetes
Notably, 40% of the children wereunder14 years of age. The average height of the children was 162.4±9.2 cm, which suggests that they had not yet reached their 
Safe use of a once‐a‐week glucagon‐like peptide‐1
New Zealand Data sheet 1. Trulicity (dulaglutide 1.5 mg/0.5

Leave a Comment

Share your thoughts, feedback, or additional insights on this topic.

Explore More